Ignyta  
自身免疫分子诊断公司

Ignyta, Inc., located in San Diego, California, is a trailblazing biotechnology company catalyzing personalized medicine with integrated Rx/Dx solutions for cancer and immunology. Our goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells or reactivate the immune system for the customized treatment of cancer patients. We will achieve this goal by leveraging our proprietary cancer and immunology genomic and epigenomic knowledge bases to discover novel targets and deliver the next generation of targeted therapeutics accompanied by highly informative biomarkers for patient selection, treatment, and monitoring.

The company was originally launched in August 2011 by Jonathan E. Lim, M.D., former president, CEO, and board director of Halozyme Therapeutics, Inc., and Gary S. Firestein, M.D., director of the Clinical and Translational Research Institute, Dean and Associate Vice Chancellor of Translational Medicine, and Professor of Medicine at UC San Diego. In May 2013, Ignyta acquired Actagene Oncology, Inc., which had been co-founded by Patrick O’Connor, Ph.D., former CEO of Actagene and Global Research Therapeutic Area Head for Oncology at Pfizer.